Preclinical Imaging

临床前成像

基本信息

批准号：
7826836
负责人：
RICHARD V MAZURCHUK
金额：
$ 15.6万
依托单位：
ROSWELL PARK CANCER INSTITUTE CORP
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7826836
关键词：
Angiogenesis Inhibitors Animal Disease Models Animals Area Arts Basic Science Biotechnology Blood Vessels Boston Budgets Buffaloes Cancer Center Support Grant Cancer Detection Chemicals Clinical Research Computer software Custom Data Data Analyses Data Set Development Diffusion Discipline of Nuclear Medicine Drug Delivery Systems Drug Kinetics Electronics Faculty Fostering Functional Magnetic Resonance Imaging Gadolinium DTPA Goals Grant Hour Housing Human Image Image Analysis Image Cytometry Imagery Imaging Techniques Imaging technology Knowledge Label Laboratories Lanthanoid Series Elements Life Lysine Magnetic Resonance Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Malignant Neoplasms Maps Methodology Methods Molecular Molecular Weight Neoplasms in Vascular Tissue Optics Permeability Pharmacologic Substance Phenotype Physiology Protocols documentation Recruitment Activity Research Research Personnel Resolution Resources Roswell Park Cancer Institute Screening procedure Sensitivity and Specificity Services Spectrum Analysis Stress Tests System Techniques Therapeutic Three-dimensional analysis Time Training Transgenic Mice Treatment Efficacy Tumor Oxygenation Universities Validation Visual base blood oxygen level dependent cohort cost data acquisition design digital fluorescence imaging image processing in vivo instrumentation interest intravital microscopy magnetic field member multimodality new technology novel optical imaging pharmacodynamic model pre-clinical programs research study response tool tumor

项目摘要

The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB). The aim is to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (< 50 urn2 in-plane spatial and < 100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision¿ 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

RPCI 临床前成像资源 (PIR) 的目标是推进小动物成像分子、细胞和生物系统水平的方法学是通过促进发展来实现的。新颖的基础科学和临床研究，促进生物技术的进步，促进发展 PIR 目前提供新的药物并评估体内药物输送和治疗效果。定制的磁共振 (MR) 方案旨在回答与以下相关的特定问题：(i) 癌症检测，(ii) 肿瘤血管功能，(iii) 治疗反应，(iv) 动物表型分析和 (v) 此外，该资源还提供全身荧光模型。对活体动物进行成像，并促进与大学的合作 microPET 研究布法罗（布法罗）的目标是提供随时可用的无创、最先进的方法和培训。 CCSG 会员可以以实惠的价格使用 Vivo 成像技术 PIR 7 天 24 小时提供服务。天/周。提供三种一般类型的 MR 服务：(a) 获得高水平的仪器和专业知识分辨率（< 50 urn2 面内空间和 < 100 ms 时间）异核成像和光谱数据， (b) 用于定量图像分析的专业知识和软件，以及 (c) 2D 和 3D 数据集的可视化探测结构/功能关系的 MR 仪器包括 4.7 T 宽孔（33 cm）磁铁。将布鲁克的 Avance 平台与 ParaVision 相结合¿ 4.0操作系统，屏蔽Accustar梯度和数字 MR 系统代表了现有的最高磁场强度扫描仪。 200 英里的 RPCI 最近扩展的服务包括全身体内光学和多光谱。还提供使用 MR 兼容窗室的活体显微镜 (IVM)。用于 MR 验证的荧光成像数据采集、硬拷贝、显示、定性/定量。对数字采集的数据集进行分析和 3D 渲染作为退款服务提供。该资源由 5 个计划使用，99% 的用户是 CCSG 会员，价值 65,218 美元。请求的支持占总运营预算的 12%。